BMS 309403

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome
   S Laouirem, A Sannier, E Norkowski, F Cauchy, S Doblas, PE Rautou, M Albuquerqu, P Garteiser, L Sognigbé, J Raffenne, BE van Beers, O Soubrane, P Bedossa, J Cros, V Paradis
   Oncogene, 2018;0(0):.
2. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.
   Furuhashi et al.
   Nature, 2007;447:959
3. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
   Sulsky et al.
   Bioorg.Med.Chem.Lett., 2007;17:3511
4. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase.
   Lin et al.
   PLoS ONE, 2012;7:e44570
5. Pre-emptive pharmacological inhibition of fatty acid-binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism
   Y Chen, Y Dai, K Song, Y Huang, L Zhang, C Zhang, Q Yan, H Gao
   Cell Death & Disease, 2021;12(6):572.

Product Datasheets